Structure-Guided Optimization of Inhibitors of Acetyltransferase Eis from Mycobacterium tuberculosis

Ankita Punetha, Huy X. Ngo, Selina Y.L. Holbrook, Keith D. Green, Melisa J. Willby, Shilah A. Bonnett, Kyle Krieger, Kyle Krieger, Emily K. Dennis, James E. Posey, Tanya Parish, Tanya Parish, Oleg V. Tsodikov, Oleg V. Tsodikov, Sylvie Garneau-Tsodikova, Sylvie Garneau-Tsodikova

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

The enhanced intracellular survival (Eis) protein of Mycobacterium tuberculosis (Mtb) is a versatile acetyltransferase that multiacetylates aminoglycoside antibiotics abolishing their binding to the bacterial ribosome. When overexpressed as a result of promoter mutations, Eis causes drug resistance. In an attempt to overcome the Eis-mediated kanamycin resistance of Mtb, we designed and optimized structurally unique thieno[2,3-d]pyrimidine Eis inhibitors toward effective kanamycin adjuvant combination therapy. We obtained 12 crystal structures of enzyme-inhibitor complexes, which guided our rational structure-based design of 72 thieno[2,3-d]pyrimidine analogues divided into three families. We evaluated the potency of these inhibitors in vitro as well as their ability to restore the activity of kanamycin in a resistant strain of Mtb, in which Eis was upregulated. Furthermore, we evaluated the metabolic stability of 11 compounds in vitro. This study showcases how structural information can guide Eis inhibitor design.

Original languageEnglish
Pages (from-to)1581-1594
Number of pages14
JournalACS Chemical Biology
Volume15
Issue number6
DOIs
StatePublished - Jun 19 2020

Bibliographical note

Publisher Copyright:
Copyright © 2020 American Chemical Society.

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine

Fingerprint

Dive into the research topics of 'Structure-Guided Optimization of Inhibitors of Acetyltransferase Eis from Mycobacterium tuberculosis'. Together they form a unique fingerprint.

Cite this